Aggrecan is one of the most important structural components of joint cartilage, and members of the metalloprotease (MMP) and ADAM (a disintegrin and metalloproteinase) protease families have been shown to degrade aggrecan in vivo. A robust assay for aggrecan-degrading activity suitable for high-throughput screening (HTS) was set up and measured using AlphaScreen™. In this technology, beads brought into proximity through cross-linking and stimulated with laser light generate a signal through luminescent oxygen tunneling, the outcome of which is a time-resolved fluorescent signal. Specific antibodies to the carbohydrate side chains of aggrecan were harnessed to create a scaffold whereby aggrecan could form a crosslink between donor and acceptor AlphaScreen detector beads. Digested aggrecan, which failed to form a cross-link, generated no signal, so that inhibitors of the digestion could be detected as a restoration of signal. The development of this assay and its validation for HTS are described in this report. (Journal of Biomolecular Screening 2003:149-156) 
INTRODUCTION
I NCREASED CATABOLISM OF AGGRECAN is an important aspect of the pathological process leading to the degeneration of articular cartilage in arthritic joint disease. Loss of the sulphated glycosaminoglycans of the aggrecan molecule progressively destroys the structural and functional integrity of the intricate matrix of proteins that comprise cartilage, increasingly rendering the tissue less capable of resisting the physical loads applied during joint articulation. With time, this breakdown results in irreversible cartilage damage. 1, 2 Aggrecan is a proteoglycan of molecular weight at least a million, one of many structural proteins that form the complex matrix of cartilage. Digestion of aggrecan in the matrix is accomplished through hydrolysis of specific peptide bonds located within the protein core. Experimentally, the most well-characterized enzymes contributing to this process are zinc-dependent metalloproteases (MMPs), a family of more than 25 enzymes. However, the proteases now believed to be principally responsible for aggrecan degradation are the aggrecanases, members of the "a disintegrin and metalloproteinase with thrombospondin motifs" (ADAMTS) gene family. Two aggrecanase isoforms, Aggrecanase-1 (ADAM-TS4) and Aggrecanase-2 (ADAM-TS5 or 11) , have been recently identified. 3, 4 Model culture systems for studying cartilage aggrecan catabolism [5] [6] [7] [8] have established that aggrecanase-like activity is primarily responsible for the early stages of catabolism and loss of aggrecan from articular cartilage, preceding overt collagen catabolism and disruption of tissue integrity. At later stages, when collagen catabolism is demonstrable, there is evidence for MMP-mediated degradation of the small proportion of aggrecan remaining in the tissue, in addition to aggrecanase activity. Thus, inhibition of aggrecan-cleaving activity can be predicted to be of therapeutic benefit in retarding the progression of osteoarthritis.
Methods that have been used for assessing aggrecan cleavage have been based on enzyme digestion of peptides or domains of the molecule or the native molecule itself. A survey of already available methods [9] [10] [11] [12] revealed several potential disadvantages in adapting them for high-throughput screening (HTS). The process of aggrecan digestion by aggrecanase is complex in that there are several cleavage sites, some more preferred than others, in the aggrecan molecule. [13] [14] [15] [16] Although many investigators use peptidic substrates, we felt that preselection of a single cleavage site could restrict or bias the discovery of novel compounds in HTS. In addition, to detect cleavage, noncommercially available or expensive antibodies directed at the neoepitopes generated after digestion by specific enzymes were often used, and such assays required separation steps. After an extended search for a robust and generally applicable method for HTS to identify inhibitors of aggrecancleaving enzymes such as aggrecanases and MMPs, we ultimately found that we could create a simple, homogeneous method to detect the disintegration of aggrecan using luminescent oxygen channeling.
The AlphaScreen™ screening platform (Packard BioSignal) uses "Amplified Luminescent Proximity Homogeneous Assay" technology in which 2 small beads (~250-nm diameter), a "donor" bead and an "acceptor" bead, are brought into proximity by a specific biological interaction. Upon illumination with laser light at 680 nm, a photosensitizer in the donor bead converts ambient oxygen to singlet-state oxygen. Because of the high concentration of photosensitizer, 1 donor bead emits up to 60,000 singlet oxygen molecules per second, thus creating a very high signal amplification. The excited singlet-state oxygen molecules diffuse no more than 200 nm before rapidly decaying. If the acceptor bead is in close proximity to the donor bead, the singlet-state oxygen molecules will react with thioxene groups in the acceptor beads, generating chemiluminescence at 370 nm, which immediately transfers energy to fluorescent acceptors in the same bead. These acceptors shift the emission wavelength to 520 to 620 nm. The emission has a comparatively long half-life of 0.3 sec, and so the measurement can take place in time-resolved mode (20-msec delay). Thus, the effect of test compounds on a specifically engineered biological interaction can be measured by a change in the AlphaScreen signal.
Here we describe the setting up and validation of an AlphaScreen method for capturing aggrecan between donor and acceptor beads, enabling us to quantitate the loss of signal after aggrecan proteolysis by any targeted enzyme.
MATERIALS AND METHODS

Buffers
Aggrecanase digestion buffer was 20 mM Tris-HCl, pH 7.4 + 10 mM CaCl 2 + 0.05% Brij. AlphaScreen assay buffer was 25 mM HEPES, 100 mM NaCl (pH 7.4) + 0.1% bovine serum albumin (BSA). No sodium azide was included in any of the buffers because the AlphaScreen method is sensitive to azide at > 0.001%.
Enzyme and substrates
Human chondrocytes, using cartilage obtained from patients who had undergone knee replacement surgery, were prepared according to standard protocols. 17 The templates for the polymerase chain reaction (PCR) were human chondrocyte total cDNA. Human Aggrecanase-1 cDNA was isolated by PCR using Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA) in the presence of 5% DMSO for 36 cycles in which each cycle consisted of 94°C/30 sec, 56°C/30 sec, and 68°C/4 min. The primers for the PCR reaction were AACGAATTCACCATGTCCCAGACAGGCTCGCAT and GATGCAATGGAGCCTCTGGTT for the 5′ half of the cDNA and AACGCGGCCGCAGCCGGGATAGTGAGGTTATT and TCAACATGCTCCATGACAACT for the 3′ half of the cDNA. The 2 halves were joined together at the unique BamHI site located at nucleotides 1594 to 1599, and the final construct spanned nucleotides 401 to 2930 of the reported cDNA sequence, GenBank accession number NM_005099. The resulting cDNA was subcloned into a mammalian expression vector, pCDNA3+ (Invitrogen, Carlsbad, CA), and was designated pcDNA3-Agg-1. The sequence of the final construct was confirmed by DNA sequencing using Dye Terminator Cycle Sequencing on an ABI PRISM 377 Sequencing system (Perkin-Elmer, Shelton, CT).
Human 293 cells (ATCC, Rockville, MD), an embryonic kidney cell line, were grown in Dulbecco's Modified Eagle medium, supplemented with 10% heat-inactivated fetal bovine serum and 1× antibiotic-antimycotic solution (all Life Technologies, Inc., Baltimore, MD) at 37°C in a humidified CO 2 incubator. Cells were stably transfected with the pCDNA3-Agg-1 expression vector using the LIPOFECTAMINE PLUS reagent (Life Technologies, Inc.). Clones were then selected by incubation with G418 (Life Technologies, Inc.) at a concentration of 400 µg/mL; the clone selected for further work was designated 293-Agg-1. For producing enzyme on a larger scale, cells were grown until reaching confluence and were then switched to serum-free DMEM. For each T-175 flask, 25 mL DMEM was added. Enzyme-rich medium was harvested 3 days later. To prevent extraneous digestion by contaminating cellular enzymes, protease inhibitor cocktail set III (Calbiochem, San Diego, CA) containing 10 µM CGS 27023A 18 (a nonspecific MMP inhibitor) was diluted 1:100 into the supernatant before aliquots were stored at -70°C.
Aggrecan from bovine nasal cartilage or human articular cartilage was prepared by standard methods 12 and stored lyophilized at -20°C or in solution in phosphate-buffered saline (pH 7.4) (PBS) at -80°C.
Chondroitinase ABC (ch-ABC) was obtained from Sigma (St. Louis, MO). Digestion of aggrecan chondroitin sulfate (CS) with ch-ABC was carried out by standard methods. 16 
Antibodies
Mouse anti-chondroitin sulfate (clone CS-56 ascites, 0.6 mg/ mL IgM) was purchased from Sigma (St. Louis, MO), affinity-purified goat anti-mouse µ from Sigma and Southern Biotechnology (Birmingham, AL), biotinylated rabbit anti-mouse γ1 (b-anti-γ1) (1 mg/mL) from Cortex Biochem (San Leandro, CA), and antibody to keratan sulfate (KS) (clone 5D-4, purified mouse IgG1, 100 µg/mL) and anti-6-sulfated chondroitin sulfate (clone 3B-3, purified mouse IgM, 100 µg/mL) from ICN Biomedicals (Costa Mesa, CA).
IgM was purified from 1-mL CS-56 ascites using an ImmunoPure IgM purification kit from Pierce Chemicals (Rockford, IL), as recommended by the manufacturer. The recov-ered IgM (0.3 mg) was coupled to biotin using methods previously described for IgG. 19 
AlphaScreen reagents
Streptavidin-coated donor beads were purchased from PackardBiosignal (Montreal, Canada), as were unconjugated acceptor beads. All manipulations involving AlphaScreen beads were done under subdued lighting. Unconjugated acceptor beads were coupled to goat IgG anti-mouse µ Sigma, unless otherwise stated by reductive amination using sodium cyanoborohydride, following the method provided by the manufacturer. The first batches were made using 5-mg beads and 30 µg of anti-µ. Assuming a 90% coupling efficiency, this represented approximately 5.4 µg anti-µ/mg beads. Assuming 90% recovery of the beads after processing, and with a final volume after coupling of 200 µL, the stock concentration was 22.5 mg beads/mL and 122 µg anti-µ/mL.
Preparation of the coupling complex and AlphaQuest detection
The detection complex consisted of 5 components: CS-56 (anti-CS) ascites (1:3000), 5D-4 (anti-KS) (1:1000), b-anti-γ1 (1:5000), anti-µ acceptor beads (1:50), and streptavidin donor beads (1:50 of 5 mg beads/mL as supplied). Dilutions of each were made in assay buffer as indicated, and then equal volumes were mixed together in the order listed. Then, 25 µL of the mix was added to 5 µL aggrecan already present in each well. Plates were immediately covered with aluminum foil lids, shaken to mix, and centrifuged briefly. They were incubated for at least 90 min before reading in the AlphaQuest.
Aggrecanase digestion of aggrecan with time
A time course experiment was set up in which aggrecan digestion was monitored at room temperature (RT). The method described was designed to minimize differences between time points introduced by evaporation of small volumes in plate wells. The digestion step was set up in time-reversed mode so that the detection step was carried out all at one time. Equal volumes of aggrecan (200 ng/mL) and aggrecanase supernatant (1:50) were mixed and incubated at RT in a closed microfuge tube. Aliquots were removed at the required time points and stored on ice until the detection step. Detection was carried out in triplicate using 20 µL of the digestion mix plus 25 µL of the usual antibody/bead mix and 90min incubation at RT.
RESULTS
Initial construction and testing of the detection reagent complex
A scaffold or reagent complex was devised to hold the aggrecan between the donor and acceptor beads. The KS and CS side chains of the aggrecan molecule are distributed along the molecule, but in general, the CS are clustered away from the KS chains. We took advantage of this clustering to capture the aggrecan between the 2 bead types, using antibodies specific for CS or KS. Then, each of these antibodies was specifically linked through further antibodies to either a donor or an acceptor bead, being careful to avoid unwanted cross-reactions. The CS-56 IgM anti-CS antibody is commercially supplied as an ascites preparation; in addition, to avoid having to purify this antibody on a large scale, a purified goat antiµ was coupled directly to acceptor beads to bind anti-CS. Biotinylated anti-mouse γ1 (b-anti-γ1), in conjunction with streptavidin-coated donor beads, was used to capture the 5D4 (mouse IgG1) anti-KS. The scaffold scheme is shown in Figure 1 .
Our first experiments examined whether cross-linking of bovine aggrecan was actually detectable by this method, which uses a very large molecular complex. Antibody dilutions were selected to yield around 5 ng per 5 µL assay buffer. In the first experiment, bovine aggrecan was titrated to demonstrate whether cross-linking of the donor and acceptor beads could be detected. Detection complex was prepared and used to cross-link aggrecan as detailed in the Materials and Methods section. The results in Figure 2A show that a signal was obtained that was proportional to the amount of aggrecan present. To confirm that the system could detect the digestion by aggrecanase of its aggrecan substrate, aggrecan (1.6 µg/ mL assay buffer) was incubated with an equal volume of aggrecanase-rich culture supernatant (1:50 in assay buffer) or with buffer alone for 4 h at 37°C. Aggrecan at 1.6 µg/mL was also incubated at RT for 4 h to provide a control for the possible breakdown of aggrecan incubated at 37°C. After incubation, serial doubling dilutions of the 3 aggrecan treatments were prepared, and 5 µL of each was added to plate wells and incubated with detection complex as before. The results are shown in Figure 2B of aggrecan with aggrecanase was clearly shown to abolish its ability to cross-link the detection complex. Incidentally, incubation of aggrecan alone at 37°C (compared to RT) was also shown to decrease the signal, indicating some aggrecan breakdown during the incubation. The aggrecan concentration of 2 ng/well seemed to be maximal because 4 ng/well gave an equal or perhaps lower signal, suggesting a formation of soluble complexes due to excess antigen. Having shown initial success with this system, the beads were titrated. Keeping the antibody concentrations the same and adding aggrecan as before at 2 ng/well, the beads were titrated out from the initially selected 1:50 dilution (Fig. 3) . Although in this experiment the donor beads do not reach a limiting dilution, in later experiments, further dilution was shown to decrease signal. Thus, a 1:100 dilution for the anti-µ acceptor beads and 1:200 dilution for the SA donor beads was selected for subsequent experiments. Other reagents were titrated similarly, and the optimal concentrations were found to be close to those already in use: these are detailed later in the protocol for the HTS assay.
Comparison of conditions for coupling anti-to acceptor beads
Conditions for the coupling of beads were initially those recommended by the manufacturer and involved a 2-day incubation of the anti-µ at 37°C. Before scaling up to batches large enough to supply screening, coupling for 1 or 2 days at room temperature was also compared because it was felt that the activity of the antibody could have been decreased by the long incubation. In addition, affinity-purified goat IgG anti-µ from Southern Biotechnology, Inc. was compared with the original Sigma antibody. In these experiments, the beads were directly cross-linked using biotinylated purified CS-56 (IgM), thus eliminating use of anti-KS, anti-CS, or aggrecan. The results shown in Figure 4 show that the original condition of 2 days at 37°C yielded the best activity and that the Sigma antibody was preferable. Similar results were found when aggrecan was used to cross-link the beads with the usual detection complex. In similar experiments, it was determined that coupling times of 3 days versus 2 days at 37°C yielded about 85% activity, again indicating that the originally suggested conditions were optimal. Finally, using the manufacturer's conditions, scale-up to 50mg batches suitable for screening was found to yield activities very similar to the optimal smaller batches.
Identification of an optimal substrate for HTS
To determine the species of aggrecan giving the greatest signal for screening, bovine and human aggrecan were compared as substrates. The monoclonal antibody 3B3 recognizes the "stubs" of chondroitin sulfate side chains after their digestion with ch-ABC. This antibody is generally held to be tighter binding than CS-56, which recognizes the intact side chain, and it was thought that this Ch-ABC-treated or untreated bovine and human aggrecan (10 µL/well, 200 ng/mL) were incubated at RT overnight after addition of 10 µL aggrecanase (1:50) or buffer alone. The antibody/bead detection complexes, made up as before but including either 3B3 or CS-56 at equivalent amounts, were added as appropriate and the AlphaQuest signal read after a 90-min incubation at RT. The results shown in Figure 5 suggest that chondroitinase-treated aggrecan of human or bovine origin is a poorer substrate for aggrecanase than the corresponding untreated aggrecan. The untreated bovine aggrecan gave a higher signal with the detection complex than human aggrecan, and the amount digested was consistently greater. Native bovine aggrecan was therefore selected for HTS.
Aggrecanase digestion of aggrecan with time
A time course experiment was set up as described in the Materials and Methods section, in which aggrecan digestion at RT was monitored. The results (Fig. 6) show that digestion of aggrecan was essentially complete by around 5 h. As for the experiment in Figure 2B , some breakdown of the aggrecan was also evident with increased time even without enzyme. Nevertheless, the S:BG ratio was greatest at the later time points, when the digestion was at its most complete. Therefore, because it was also more convenient for HTS purposes, an overnight incubation was selected.
Inhibition of aggrecanase digestion with known MMP inhibitor compounds
The activity of 3 nonspecific inhibitors of MMPs known also to inhibit aggrecanase was tested in a dose-response assay (Fig. 7) using the conditions set in previous experiments. The rank orders for the IC 50 values for these 3 compounds are the same as those we have determined using alternative assay methods for aggrecanase (e.g., in vitro digestion of cartilage by interleukin 1-induced aggrecanase activity). [6] [7] [8] 
Method used in HTS
Using the assay development results, the HTS assay was set up as follows. In a 384-well flat-bottom white plate, 3 µL compound, 5% DMSO to determine the "nonspecific" signal, or 38 µM of the nonspecific MMP inhibitor CGS35764 as positive control (com- pounds 5 µM/0.5% DMSO final) was added. Then, 10-µL additions were made of aggrecanase-containing supernatant (1:100 dilution final) followed by 10 µL aggrecan (90 ng/mL final). Plates were sealed and incubated at RT for 24 h. A mix containing 112.5 µg/mL anti-mouse µ acceptor beads, 25 µg/mL streptavidin donor beads, 0.2 µg/mL CS-56 anti-CS, 0.33 µg/mL 5D4 anti-KS, and 0.2 µg/mL b-anti-γ1 was prepared, and 25 µL was added into each well in the dark. After a 2-h incubation at RT in the dark, plates were counted on the AlphaQuest (Model αQ) optical plate reader set at 1 sec per well.
Performance of the assay in HTS
About 400,000 synthetic compounds were screened for this assay. With a cutoff set at -60% change, 508 compounds were further evaluated and 323 compounds were confirmed active. Of these, 130 compounds were selected on chemical criteria as the most interesting, and 66 of these gave viable IC 50 values, with potencies ranging from 100 nM to 9 µM. The assay performed well, routinely giving signal-to-background values around 20:1 and an overall Z′ factor of 0.82 ± 0.036. Figure 8 shows dose-response curves of a sample of 9 hits identified in the HTS campaign. Interestingly, and not apparent from simply comparing IC 50 values, the maxima of the curves produced by different compounds are not the same. We have also seen this in other assay methods with different readouts in which aggrecan is used as a substrate, and therefore it seems not to be related to the method of detection. Possibly the cleavage of aggrecan, a complex substrate with multiple potential cleavage sites and a mixture of polymeric sizes, causes these different inhibition maxima by the individual compounds. If so, this indication of possible differences in the mechanism of action could constitute useful additional information in the process of selecting a lead. Representative dose-response curves for 7 synthetic compounds from the screen for aggrecanase inhibitors. Each point is the mean of 2 determinations. IC 50 values and maximum cps for each compound were calculated using a sigmoidal dose-response curve-fitting routine (see Fig. 7 ). The maximum cps achieved with compound F was similar to the "no-enzyme" control.
DISCUSSION
Before the introduction of AlphaScreen™ technology, several methods of assaying the action of aggrecanase had been rejected for use in HTS because of unsuitability of the assay for screening. Using AlphaScreen, we were able to move forward into screening very quickly. The method described here is homogeneous and scaleable, and the read time is also fast (2.3 min for a 384-well plate). In addition, the high excitation wavelength of 680 nm and the time-resolved measurement is beneficial in the context of screening where prompt fluorescence interference can be a problem with HTS of diverse compound libraries. The ALPHA signal is less restrictive than fluorescence energy transfer (FRET) systems in the molecular distances allowable between signaling moieties (200 nm for ALPHA vs. 7 nm for FRET), allowing much greater scope in assay design. In this case, a very large molecular complex was constructed using 4 antibodies and a large molecular weight antigen, yet a good signal was obtained. It was possible to purchase beads suitable for coupling to proteins in-house, and the method provided worked well. We were easily able to test various antibodies and substrates in this format, and it allowed us to confirm observations made by others 9 that ch-ABC-treated aggrecan is a poorer substrate for aggrecanase than the native molecule. The method is also directly applicable to any enzyme that cleaves aggrecan: with appropriate "titration in" for time and concentration, any test enzyme can be substituted for the Aggrecanase-1 used here. The compounds resulting from the screen were not apparently unduly selected by the screening method, being structurally diverse and able to be confirmed at a reasonable rate in alternative readouts using the same substrate.
With any assay readout, its limitations in screening become apparent only after the introduction of the test compound libraries because most assay methods, especially the homogeneous formats so favorable to HTS campaigns, will encounter compounds that distort the result due to interference with the measurement. The most obvious interferences with AlphaScreen may be expected from oxidizing and reducing compounds. However, it remains difficult to predict the outcome from first principles until several full screens have been carried out and the results compared. For example, fluorescence polarization, initially expected to be less error prone due to its ratiometric output, is still sensitive to compounds that quench the fluorescent signal, and such screens return a high number of hits that do not repeat in assays using alternative readouts. 21 Such findings have diverted efforts from initial formats where FITC was used, toward substitution of red fluors with higher emission wavelengths, to avoid interference by yellow compounds that are frequent in archive screening libraries. On the other hand, our experiences with scintillation proximity assaybead-based screens (readout at 405-420 nm) suggest that compound interference with this readout is less of an issue, even though yellow compounds would again be predicted to pose a problem.
The use of AlphaScreen is relatively new in screening, and it thus remains to be seen how well it will perform ultimately because the real proof of utility comes with confirmation of activities in downstream functional assays. In general, however, it has been technically very successful in our hands and should definitely be considered by any laboratory as an addition to its repertoire of measurement techniques.
